-
Your prediction
Adverum Biotechnologies Inc. Stock
Pros and Cons of Adverum Biotechnologies Inc. in the next few years
Pros
Cons
Performance of Adverum Biotechnologies Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies Inc. | - | - | - | - | - | - | - |
| Krystal Biotech | 2.590% | 5.455% | -19.051% | -21.701% | -23.784% | 127.451% | - |
| Ardelyx Inc. | 3.180% | -9.044% | -3.726% | -51.496% | -35.992% | 407.830% | -48.325% |
| Evolus Inc | -2.350% | 6.918% | -16.667% | -25.439% | -19.048% | -34.615% | 84.783% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Examining the financials of Adverum Bio, a company within the Biotechnology & Medical Research sector, reveals a mixed picture characterized by significant challenges. Despite the potential that the biotechnology industry offers, particularly with advancements in medical research and therapies, Adverum Bio's financial metrics indicate a period of struggle, marked by negative earnings, hefty operating losses, and a concerning trend in revenue growth. The company's market capitalization, limited revenue, and escalating expenses add to a narrative that calls for careful scrutiny.
Pros of Adverum Bio's Financials:
Strong Market Capitalization: With a market capitalization of approximately $156.71 million, Adverum Bio retains a presence in the biotechnology space. A robust market cap can attract institutional investors and lend credibility to a company within this highly volatile industry.
Comments
